Joshua Richter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua Richter has a total of 479 co-authors. Here are the top co-authors by number of shared publications:
- Sundar Jagannath
Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
68 shared publications - Hearn Jay Cho
Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
66 shared publications - Samir Parekh
Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
59 shared publications - Santiago Thibaud
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
59 shared publications - Shambavi Richard
Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
59 shared publications - Larysa Sanchez
Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
54 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Blood Cancer Journal
Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study
- 1 October 2026
- Published by Springer Nature in Blood Cancer Journal
Open AccessInfection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (25) , 2447-2459
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas
Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence of systemic involvement or myeloma defining events. Approximately 50% of SPs will progress to symptomatic myeloma within 5 years after initial definitive local radiotherapy. Increased availability of improved diagnostic and monitoring tools has increased the sensitivity of detection of additional lesions and marrow involvement and has implications for the follow-up strategy after treatment. Thus, the definitions and requirements for the diagnosis and follow-up of SPs are evolving. The diagnosis of SP requires the careful exclusion of multiple myeloma (MM) that would require systemic therapy, by using all the available methods to detect systemic disease (advanced imaging, sensitive BM assessment methods, blood and urine tests). Local radiotherapy remains the mainstay of therapy, and despite the availability of innovative drugs for MM, the clinical benefit of systemic therapy currently remains poorly defined. The International Myeloma Working Group provides here updated recommendations for the diagnosis, evaluation, treatment, and response assessment of patients with SPs, incorporating recent data and advances in diagnostic tools.
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (25) , 2447-2459
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas
Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence of systemic involvement or myeloma defining events. Approximately 50% of SPs will progress to symptomatic myeloma within 5 years after initial definitive local radiotherapy. Increased availability of improved diagnostic and monitoring tools has increased the sensitivity of detection of additional lesions and marrow involvement and has implications for the follow-up strategy after treatment. Thus, the definitions and requirements for the diagnosis and follow-up of SPs are evolving. The diagnosis of SP requires the careful exclusion of multiple myeloma (MM) that would require systemic therapy, by using all the available methods to detect systemic disease (advanced imaging, sensitive BM assessment methods, blood and urine tests). Local radiotherapy remains the mainstay of therapy, and despite the availability of innovative drugs for MM, the clinical benefit of systemic therapy currently remains poorly defined. The International Myeloma Working Group provides here updated recommendations for the diagnosis, evaluation, treatment, and response assessment of patients with SPs, incorporating recent data and advances in diagnostic tools.
- Open Access
- 25 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study
There is a paucity of data in frail patients with multiple myeloma (MM) receiving bispecific antibodies (bsAbs). In LINKER-MM1 (NCT03761108), linvoseltamab (human BCMA×CD3 bsAb) demonstrated high response rates and a generally manageable safety profile in relapsed/refractory (RR)MM. This LINKER-MM1 post hoc analysis evaluated outcomes of linvoseltamab 200 mg in patients categorized for frailty using the International Myeloma Working Group Frailty Proxy (IMWG-FP), Simplified Frailty Score (SFS), and patient-reported frailty phenotype (PRFP). As of July 23, 2024, 117 patients received linvoseltamab (median follow-up: 21.3 months). The percentage of frail patients varied by measure: IMWG-FP, 27.4%; SFS, 26.5%; and PRFP, 20.5% (8/4 patients were excluded due to missing IMWG-FP/PRFP scores, respectively). Objective response rates in non-frail and frail groups, respectively, were: IMWG-FP, 72.7% and 65.6%; SFS, 69.8% and 74.2%; PRFP, 73.0% and 62.5%. Incidence of Grade 3/4 treatment-emergent adverse events was consistent across non-frail and frail groups (IMWG-FP: 72.7% and 75.0%; SFS%: 73.3% and 74.2; PRFP: 74.2% and 70.8, respectively). Clinical outcomes were consistent in non-frail and frail groups, indicating a favorable risk–benefit profile for linvoseltamab in the frail patients with RRMM from LINKER-MM1. Continued evaluation of linvoseltamab in frail patients with RRMM in clinical trials and real-world settings is warranted.
- 25 July 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessLinvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study
There is a paucity of data in frail patients with multiple myeloma (MM) receiving bispecific antibodies (bsAbs). In LINKER-MM1 (NCT03761108), linvoseltamab (human BCMA×CD3 bsAb) demonstrated high response rates and a generally manageable safety profile in relapsed/refractory (RR)MM. This LINKER-MM1 post hoc analysis evaluated outcomes of linvoseltamab 200 mg in patients categorized for frailty using the International Myeloma Working Group Frailty Proxy (IMWG-FP), Simplified Frailty Score (SFS), and patient-reported frailty phenotype (PRFP). As of July 23, 2024, 117 patients received linvoseltamab (median follow-up: 21.3 months). The percentage of frail patients varied by measure: IMWG-FP, 27.4%; SFS, 26.5%; and PRFP, 20.5% (8/4 patients were excluded due to missing IMWG-FP/PRFP scores, respectively). Objective response rates in non-frail and frail groups, respectively, were: IMWG-FP, 72.7% and 65.6%; SFS, 69.8% and 74.2%; PRFP, 73.0% and 62.5%. Incidence of Grade 3/4 treatment-emergent adverse events was consistent across non-frail and frail groups (IMWG-FP: 72.7% and 75.0%; SFS%: 73.3% and 74.2; PRFP: 74.2% and 70.8, respectively). Clinical outcomes were consistent in non-frail and frail groups, indicating a favorable risk–benefit profile for linvoseltamab in the frail patients with RRMM from LINKER-MM1. Continued evaluation of linvoseltamab in frail patients with RRMM in clinical trials and real-world settings is warranted.
- Open Access
- 14 July 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (18) , 2169-2177
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma
1. Multiple myeloma (MM) is a hematologic cancer characterized by the accumulation of neoplastic plasma cells in the bone marrow [1,2]. These malignant cells produce monoclonal proteins that are de...
- 14 July 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (18) , 2169-2177
Open AccessEffectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma
1. Multiple myeloma (MM) is a hematologic cancer characterized by the accumulation of neoplastic plasma cells in the bone marrow [1,2]. These malignant cells produce monoclonal proteins that are de...
- Open Access
- 10 July 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (10) , 2116-2128
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison
Multiple myeloma (MM) is an incurable plasma cell malignancy with poor prognosis in patients with relapsed/refractory (RR) disease, despite recent therapeutic advances [1–3]. B-cell maturation anti...
- 10 July 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (10) , 2116-2128
Open AccessLinvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison
Multiple myeloma (MM) is an incurable plasma cell malignancy with poor prognosis in patients with relapsed/refractory (RR) disease, despite recent therapeutic advances [1–3]. B-cell maturation anti...
- 8 July 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (18) , 2131-2142
Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma
1. Multiple myeloma (MM) is characterized by the expansion of clonal plasma cells in the bone marrow. These clonal plasma cells produce monoclonal immunoglobulins (M-protein) and can contribute to ...
- 8 July 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (18) , 2131-2142
Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma
1. Multiple myeloma (MM) is characterized by the expansion of clonal plasma cells in the bone marrow. These clonal plasma cells produce monoclonal immunoglobulins (M-protein) and can contribute to ...
- Open Access
- 25 June 2026
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 42 (5) , 1-15
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
Assessing the comparative efficacy of novel chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (bsAb) therapies for relapsed/refractory multiple myeloma (RRMM) is crucial for informed treatment decisions. This study systematically reviewed indirect treatment comparisons (ITCs) evaluating the efficacy of approved CAR-T therapies and bsAbs in triple-class exposed RRMM. Systematic searches identified ITCs comparing the efficacy of approved BCMA- and GPRC5D-targeted therapies: elranatamab, linvoseltamab, talquetamab, teclistamab, ciltacabtagene autoleucel (cilta-cel), and idecabtagene vicleucel (ide-cel). Screening used large language models and human researchers, with full-text review and data extraction performed by two researchers. Results were synthesized qualitatively. Eleven matching-adjusted indirect comparisons (MAICs) were included; six compared bsAbs, four compared bsAbs and CAR-Ts, and one compared CAR-Ts. All MAICs were adjusted for differences in refractory status, cytogenetic risk, disease stage, and presence of extramedullary disease. Across all MAICs identified, elranatamab showed significant improvements versus teclistamab (ORR, DOR, PFS, OS); linvoseltamab showed significant improvements versus elranatamab (ORR, ≥CR), talquetamab (≥CR, DOR), teclistamab (DOR, PFS, OS), ide-cel (≥CR, DOR, PFS), and cilta-cel (DOR); ide-cel showed significant improvements versus teclistamab (OS) and elranatamab (OS); and cilta-cel showed significant improvements versus linvoseltamab (ORR, ≥VGPR, ≥CR), and ide-cel (ORR, ≥CR, DOR, PFS, OS). Although head-to-head trials are not available, the MAICs provide hypothesis-generating estimates of the relative efficacy of approved bsAbs and CAR-Ts for triple-class exposed RRMM. Based on the available evidence, linvoseltamab and cilta-cel were frequently associated with improved efficacy across a range of comparators and endpoints; however, these findings included both statistically significant and numerically favorable results and should be interpreted cautiously in light of cross-study heterogeneity and the limitations associated with unanchored MAICs.
- 25 June 2026
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 42 (5) , 1-15
Open AccessA systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
Assessing the comparative efficacy of novel chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (bsAb) therapies for relapsed/refractory multiple myeloma (RRMM) is crucial for informed treatment decisions. This study systematically reviewed indirect treatment comparisons (ITCs) evaluating the efficacy of approved CAR-T therapies and bsAbs in triple-class exposed RRMM. Systematic searches identified ITCs comparing the efficacy of approved BCMA- and GPRC5D-targeted therapies: elranatamab, linvoseltamab, talquetamab, teclistamab, ciltacabtagene autoleucel (cilta-cel), and idecabtagene vicleucel (ide-cel). Screening used large language models and human researchers, with full-text review and data extraction performed by two researchers. Results were synthesized qualitatively. Eleven matching-adjusted indirect comparisons (MAICs) were included; six compared bsAbs, four compared bsAbs and CAR-Ts, and one compared CAR-Ts. All MAICs were adjusted for differences in refractory status, cytogenetic risk, disease stage, and presence of extramedullary disease. Across all MAICs identified, elranatamab showed significant improvements versus teclistamab (ORR, DOR, PFS, OS); linvoseltamab showed significant improvements versus elranatamab (ORR, ≥CR), talquetamab (≥CR, DOR), teclistamab (DOR, PFS, OS), ide-cel (≥CR, DOR, PFS), and cilta-cel (DOR); ide-cel showed significant improvements versus teclistamab (OS) and elranatamab (OS); and cilta-cel showed significant improvements versus linvoseltamab (ORR, ≥VGPR, ≥CR), and ide-cel (ORR, ≥CR, DOR, PFS, OS). Although head-to-head trials are not available, the MAICs provide hypothesis-generating estimates of the relative efficacy of approved bsAbs and CAR-Ts for triple-class exposed RRMM. Based on the available evidence, linvoseltamab and cilta-cel were frequently associated with improved efficacy across a range of comparators and endpoints; however, these findings included both statistically significant and numerically favorable results and should be interpreted cautiously in light of cross-study heterogeneity and the limitations associated with unanchored MAICs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 1: Output of Cox Proportional Hazards Model for Multivariate PFS1 Analysis in HDM-ASCT Recipients with MM (Combined Cohort)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 1: Output of Cox Proportional Hazards Model for Multivariate PFS1 Analysis in HDM-ASCT Recipients with MM (Combined Cohort)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 6: Comparative Per-gene PGV-B Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 6: Comparative Per-gene PGV-B Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 4: Comprehensive characterization of PGV-B/C carriers with multiple myeloma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 4: Comprehensive characterization of PGV-B/C carriers with multiple myeloma